Literature DB >> 19362106

Association of botulinum neurotoxins with synaptic vesicle protein complexes.

Michael R Baldwin1, Joseph T Barbieri.   

Abstract

Botulinum neurotoxins (BoNTs) elicit flaccid paralysis by cleaving SNARE proteins within peripheral neurons. BoNTs are classified into seven serotypes, termed A-G, based on antibody cross-neutralization. Clostridia produce BoNTs as single-chain toxins that are cleaved into a di-chain protein that comprises an N-terminal zinc metalloprotease domain that is linked by a disulfide bond to the C-terminal translocation/receptor-binding domain. BoNT/A and BoNT/B utilize synaptic vesicle protein 2 (SV2) and synaptotagmin, respectively, as receptors for entry into neurons. Using affinity chromatography, BoNT/A and BoNT/B were found to bind a synaptic vesicle protein complex in CHAPS extracts of synaptic vesicles. Mass spectroscopy identified synaptic vesicle protein 2, synaptotagmin I, synaptophysin, vesicle-associated membrane protein 2, and the vacuolar ATPase-proton pump as components of the BoNT-synaptic vesicle protein complex. BoNT/A and BoNT/B possessed unique density-gradient profiles when bound to synaptic vesicle protein complexes. The identification of BoNT/A and BoNT/B bound to synaptic vesicle protein complexes provides insight into the interactions of BoNT and neuronal receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362106      PMCID: PMC2730980          DOI: 10.1016/j.toxicon.2009.01.040

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  45 in total

1.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.

Authors:  Lilia K Koriazova; Mauricio Montal
Journal:  Nat Struct Biol       Date:  2003-01

2.  Roles of complex gangliosides at the neuromuscular junction.

Authors:  R W M Bullens; G M O'Hanlon; E Wagner; P C Molenaar; Koichi Furukawa; Keiko Furukawa; J J Plomp; H J Willison
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

Review 3.  Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective.

Authors:  E A Johnson; M Bradshaw
Journal:  Toxicon       Date:  2001-11       Impact factor: 3.033

4.  Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice.

Authors:  M Kitamura; K Takamiya; S Aizawa; K Furukawa; K Furukawa
Journal:  Biochim Biophys Acta       Date:  1999-10-18

5.  Differential distribution of vesicular glutamate transporters in the rat cerebellar cortex.

Authors:  H Hioki; F Fujiyama; K Taki; R Tomioka; T Furuta; N Tamamaki; T Kaneko
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

6.  Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function.

Authors:  Roland W M Bullens; Graham M O'Hanlon; Eric Wagner; Peter C Molenaar; Keiko Furukawa; Koichi Furukawa; Jaap J Plomp; Hugh J Willison
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

7.  Characterization of synaptogyrin 3 as a new synaptic vesicle protein.

Authors:  Roger Belizaire; Cheryl Komanduri; Kerry Wooten; Ming Chen; Christina Thaller; Roger Janz
Journal:  J Comp Neurol       Date:  2004-03-08       Impact factor: 3.215

8.  Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G.

Authors:  Andreas Rummel; Tino Karnath; Tina Henke; Hans Bigalke; Thomas Binz
Journal:  J Biol Chem       Date:  2004-04-30       Impact factor: 5.157

Review 9.  Presynaptic receptor arrays for clostridial neurotoxins.

Authors:  Cesare Montecucco; Ornella Rossetto; Giampietro Schiavo
Journal:  Trends Microbiol       Date:  2004-10       Impact factor: 17.079

10.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.

Authors:  Min Dong; David A Richards; Michael C Goodnough; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  J Cell Biol       Date:  2003-09-22       Impact factor: 10.539

View more
  14 in total

Review 1.  A review of botulinum toxin use for chronic pelvic pain syndrome.

Authors:  Henry P Gottsch; Claire C Yang; Richard E Berger
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

Review 2.  Toxins from bacteria.

Authors:  James S Henkel; Michael R Baldwin; Joseph T Barbieri
Journal:  EXS       Date:  2010

3.  Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery.

Authors:  Erkan Kiris; Jonathan E Nuss; James C Burnett; Krishna P Kota; Dawn C Koh; Laura M Wanner; Edna Torres-Melendez; Rick Gussio; Lino Tessarollo; Sina Bavari
Journal:  Stem Cell Res       Date:  2011-01-19       Impact factor: 2.020

Review 4.  Inositol hexakisphosphate-induced autoprocessing of large bacterial protein toxins.

Authors:  Martina Egerer; Karla J F Satchell
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

5.  Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.

Authors:  C Bandala; A L Cortés-Algara; C M Mejía-Barradas; I Ilizaliturri-Flores; R Dominguez-Rubio; C I Bazán-Méndez; E Floriano-Sánchez; J P Luna-Arias; M Anaya-Ruiz; E Lara-Padilla
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

6.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

7.  Maturation of neurotransmission in the developing rat cochlea: immunohistochemical evidence from differential expression of synaptophysin and synaptobrevin 2.

Authors:  S He; J Yang
Journal:  Eur J Histochem       Date:  2011-01-18       Impact factor: 3.188

Review 8.  Botulinum neurotoxin for pain management: insights from animal models.

Authors:  Flaminia Pavone; Siro Luvisetto
Journal:  Toxins (Basel)       Date:  2010-12-21       Impact factor: 4.546

Review 9.  Towards new uses of botulinum toxin as a novel therapeutic tool.

Authors:  Andy Pickett; Karen Perrow
Journal:  Toxins (Basel)       Date:  2011-01-12       Impact factor: 4.546

10.  Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).

Authors:  Birgitte P S Jacky; Patton E Garay; Jérôme Dupuy; Jeremy B Nelson; Brian Cai; Yanira Molina; Joanne Wang; Lance E Steward; Ron S Broide; Joseph Francis; K Roger Aoki; Raymond C Stevens; Ester Fernández-Salas
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.